- Home
- WING vs AXSM Comparison
WING vs AXSM Comparison
Compare WING & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WING | AXSM |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.9B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | WING | AXSM |
|---|---|---|
| Price | $247.30 | $149.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 25 | 20 |
| Target Price | ★ $343.33 | $176.00 |
| AVG Volume (30 Days) | ★ 736.5K | 530.9K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ 79.44 | N/A |
| EPS | ★ 6.14 | N/A |
| Revenue | ★ $682,980,000.00 | $561,263,000.00 |
| Revenue This Year | $13.93 | $66.20 |
| Revenue Next Year | $17.91 | $57.56 |
| P/E Ratio | $40.30 | ★ N/A |
| Revenue Growth | 15.55 | ★ 65.83 |
| 52 Week Low | $204.00 | $75.56 |
| 52 Week High | $388.14 | $152.94 |
Technical Indicators
Market Signals| Indicator | WING | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 58.89 |
| Support Level | $241.12 | $144.00 |
| Resistance Level | $281.28 | $151.63 |
| Average True Range (ATR) | 13.29 | 4.54 |
| MACD | -0.47 | -0.79 |
| Stochastic Oscillator | 36.84 | 66.13 |
Price Performance
Historical ComparisonAbout WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.